Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03362060 · ClinicalTrials.gov registry record · Phase 1
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
A Phase 1 study of Metastatic Breast Cancer and Triple Negative Breast Cancer, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT03362060: Active Phase 1 study of Metastatic Breast Cancer and Triple Negative Breast Cancer, sponsored by Massachusetts General Hospital.
NCT03362060 is a Phase 1 study of Metastatic Breast Cancer and Triple Negative Breast Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03362060, a Phase 1 study of Metastatic Breast Cancer and Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer (TNBC) in participants who are HLA-A2+. The drugs involved in this study are: * PVX-410 * Pembrolizumab * Hiltonol * Montanide
Primary Outcome
The fold activation of T cells from blood of treated patients at week 10 compared to baseline
Conditions Studied
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL PVX-410
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 1 |
What the registry record for NCT03362060 still lists
NCT03362060 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03362060 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03362060 about?
NCT03362060 is a clinical study titled "PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer". This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer (TNBC) in participants who are HLA-A2+. The drugs involved in this study are: * PVX-410 * Pembrolizumab * Hiltonol * Montanide
What is the current status of trial NCT03362060?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-12-12. Estimated completion is 2027-12-30.
What conditions does trial NCT03362060 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT03362060?
The interventions under investigation include: Pembrolizumab (DRUG), PVX-410 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03362060?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03362060 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03362060's enrollment target sits among peer trials
20 119th of 139 higher than 18 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI